SCIENTIFIC CULTURE

www.sci-cult.com

SCIENTIFIC CULTURE, Vol. 12, No. 5, (2026), pp. 1460-1474
Open Access. Online & Print

DOI: 10.5281/zenodo.20818649

ASSOCIATION BETWEEN SLEEP DISTURBANCE, OBESITY, AND GLYCEMIC CONTROL AMONG PRIMARY CARE PATIENTS: A COMPREHENSIVE REVIEW

Alhanouf Ali Ahmmed[1], Mousa Mohammed Hadi[2], Manal Ali Alhomod[3], Eman Hassan Asiri[4], Amal Abdulkhalig Alhefdi[5], Aysha Yahya Alhifthi[6] and Fahad Jaber Salman Alfaifi[7]

[1]Aseer cluster, Senior registrar family medicine
[2]Aseer Cluster, Family Medicine Consultant
[3]Family medicine consultant, Aseer health cluster
[4]Family medicine consultant, Aseer health cluster
[5]Family Medicine consultant, Aseer health cluster
[6]Family medicine consultant, Aseer health cluster
[7]Registrar Family medicine, Aseer health cluster

Received: 12/04/2026
Accepted: 26/05/2026

ABSTRACT

Sleep disturbance has emerged as a major public health challenge and is increasingly recognized as a critical determinant of metabolic health. Concurrently, the prevalence of obesity and type 2 diabetes mellitus (T2DM) has risen dramatically worldwide, creating substantial clinical and economic burdens. Growing evidence indicates that sleep disorders, including insomnia, short sleep duration, poor sleep quality, circadian rhythm disruption, and obstructive sleep apnea (OSA), contribute significantly to obesity development and impaired glycemic control. These associations are mediated through complex neuroendocrine, inflammatory, autonomic, and behavioral mechanisms that influence appetite regulation, insulin sensitivity, glucose metabolism, and energy expenditure. Sleep deprivation alters the secretion of leptin, ghrelin, cortisol, growth hormone, and incretins, promoting increased caloric intake, weight gain, and insulin resistance. Furthermore, obesity contributes to sleep abnormalities through mechanical airway obstruction, systemic inflammation, and hormonal dysregulation, resulting in a bidirectional relationship between sleep disturbance and excess adiposity. Poor glycemic control itself may further worsen sleep quality through nocturia, neuropathic pain, restless leg syndrome, and glucose fluctuations, creating a self-perpetuating cycle of metabolic deterioration. Primary care settings represent the first point of contact for most patients experiencing these interconnected conditions, highlighting the importance of comprehensive assessment and integrated management strategies. This review synthesizes current evidence regarding the epidemiology, pathophysiology, clinical implications, and management of sleep disturbance, obesity, and glycemic control among primary care patients. Particular attention is given to mechanisms linking sleep and metabolic health, the impact of sleep disorders on diabetes outcomes, and practical approaches for screening and intervention in primary care. Addressing sleep health may represent an underutilized but highly effective strategy for improving obesity management and glycemic outcomes. Integrating sleep assessment into routine primary care practice may enhance patient-centered care

and reduce the long-term burden of metabolic disease.

KEYWORDS: Sleep Disturbance, Obesity, Glycemic Control, Diabetes Mellitus, Insulin Resistance, Sleep Quality, Primary Care, Obstructive Sleep Apnea, Hba1c, Metabolic Syndrome.

1. INTRODUCTION

Sleep is a fundamental biological process that plays a vital role in maintaining physiological homeostasis, metabolic regulation, cognitive function, cardiovascular health, immune competence, and overall well-being. Although sleep was traditionally viewed as a passive state of rest, contemporary research has established that sleep is a highly active physiological process essential for maintaining endocrine balance and metabolic stability. Over the past several decades, major societal and technological changes have resulted in significant alterations in sleep patterns across populations worldwide. Increasing work demands, urbanization, prolonged screen exposure, shift work schedules, and psychosocial stress have contributed to reduced sleep duration and deteriorating sleep quality among adults. Simultaneously, obesity and diabetes have emerged as some of the most pressing global health challenges of the twenty-first century, with prevalence rates reaching epidemic proportions in many countries [1,2].

The World Health Organization estimates that more than one billion adults worldwide are overweight, while hundreds of millions are living with obesity [1]. Similarly, diabetes affects over 500 million individuals globally, with projections indicating a continued increase in prevalence over the coming decades [2]. These conditions are associated with substantial morbidity, mortality, healthcare expenditures, and reductions in quality of life. Traditionally, obesity and diabetes prevention strategies have focused primarily on dietary modification and physical activity. However, emerging evidence suggests that sleep health represents an additional and potentially modifiable determinant of metabolic disease that has historically received insufficient attention within clinical practice [3].

Numerous epidemiological studies have demonstrated strong associations between sleep disturbance and adverse metabolic outcomes. Individuals experiencing chronic sleep deprivation are more likely to develop obesity, insulin resistance, metabolic syndrome, and T2DM than those obtaining adequate sleep [4,5]. Furthermore, both short sleep duration and excessively long sleep duration have been associated with increased risk of diabetes, suggesting a U-shaped relationship between sleep and metabolic health [6]. These observations have prompted growing interest in understanding the biological pathways linking sleep and metabolism.

Several mechanisms have been proposed to explain these associations. Sleep restriction influences appetite regulation through alterations in the secretion of leptin and ghrelin, hormones that play central roles in hunger and satiety. Reduced sleep duration decreases leptin concentrations while increasing ghrelin levels, resulting in enhanced appetite and increased caloric intake [7]. Experimental studies have shown that sleep-deprived individuals exhibit stronger cravings for high-calorie foods rich in carbohydrates and fats, potentially contributing to weight gain over time [8]. Additionally, sleep deprivation impairs insulin sensitivity, disrupts glucose homeostasis, and activates inflammatory pathways, all of which promote metabolic dysfunction [9].

The relationship between sleep and obesity appears to be bidirectional. While sleep disturbances can contribute to obesity development, obesity itself increases susceptibility to various sleep disorders, particularly OSA. OSA is characterized by recurrent episodes of upper airway obstruction during sleep, leading to intermittent hypoxia, sleep fragmentation, and activation of sympathetic nervous system pathways [10]. OSA affects a substantial proportion of individuals with obesity and has been independently associated with insulin resistance, poor glycemic control, and increased cardiovascular risk [11]. Consequently, obesity and sleep disorders frequently coexist and may synergistically worsen metabolic outcomes.

Among individuals with diabetes, sleep disturbances are highly prevalent and often underrecognized. Patients with T2DM frequently report insomnia symptoms, nocturnal awakenings, restless sleep, excessive daytime sleepiness, and poor sleep quality [12]. Several diabetes-related factors contribute to sleep disruption, including nocturia, peripheral neuropathy, hypoglycemic episodes, hyperglycemia, and comorbid psychological disorders [13]. Conversely, poor sleep quality may worsen glycemic control by impairing insulin sensitivity and increasing glucose variability. This reciprocal relationship creates a cycle in which metabolic dysregulation and sleep impairment reinforce one another, potentially accelerating disease progression and increasing complication risk.

The role of circadian rhythms has further expanded understanding of the relationship between sleep and metabolic health. Circadian rhythms regulate numerous physiological processes, including hormone secretion, glucose metabolism, appetite control, and energy expenditure. Disruption of circadian alignment through shift work, irregular sleep schedules, or social jet lag has been associated with obesity, metabolic syndrome, and diabetes [14].

Circadian misalignment may impair pancreatic β-cell function, alter insulin sensitivity, and promote weight gain independent of sleep duration itself [15]. These findings suggest that both sleep quantity and sleep timing are important determinants of metabolic health.

The burden of sleep disorders in primary care populations is substantial. Primary care physicians frequently encounter patients presenting with obesity, diabetes, hypertension, fatigue, and mood disorders, many of whom have underlying sleep disturbances that remain undiagnosed. Despite increasing recognition of the importance of sleep health, sleep assessments are not routinely incorporated into many primary care consultations [16]. Consequently, opportunities for early identification and intervention may be missed. Given the growing evidence linking sleep disturbance to obesity and glycemic dysregulation, integrating sleep evaluation into routine primary care practice may represent an effective strategy for improving metabolic outcomes and reducing long-term disease burden.

From a public health perspective, understanding the interplay between sleep, obesity, and glycemic control has important implications. Sleep represents a potentially modifiable risk factor that can be addressed through behavioral interventions, sleep hygiene education, weight reduction strategies, treatment of sleep disorders, and optimization of circadian health. Unlike certain nonmodifiable risk factors, sleep behaviors can often be improved through relatively low-cost interventions that may yield substantial metabolic benefits [17]. Therefore, incorporating sleep health into comprehensive obesity and diabetes management programs may enhance treatment effectiveness and improve patient outcomes.

Recent advances in sleep medicine, endocrinology, and metabolic research have generated a growing body of evidence supporting the role of sleep in metabolic regulation. However, significant gaps remain regarding optimal screening approaches, intervention strategies, and implementation within primary care settings. Furthermore, the mechanisms linking sleep disturbances with obesity and glycemic control continue to be investigated, with emerging evidence highlighting complex interactions among hormonal, inflammatory, neural, genetic, and behavioral pathways.

The present review aims to provide a comprehensive synthesis of current evidence regarding the association between sleep disturbance, obesity, and glycemic control among primary care patients. Specifically, this review examines the epidemiology of sleep disorders in primary care populations, explores biological mechanisms linking sleep and metabolic health, evaluates the impact of sleep disturbances on obesity and diabetes outcomes, and discusses practical implications for screening, prevention, and management. Through a comprehensive examination of existing literature, this review seeks to support healthcare professionals in developing integrated approaches to metabolic health that recognize the critical importance of sleep as a determinant of patient outcomes.

2. METHODOLOGY

This comprehensive review was conducted using a narrative synthesis approach to evaluate current evidence regarding the association between sleep disturbance, obesity, and glycemic control among primary care patients. A structured literature search was performed using electronic databases including PubMed/MEDLINE, Scopus, Embase, Web of Science, Cochrane Library, and Google Scholar. The search strategy incorporated combinations of Medical Subject Headings (MeSH) terms and keywords including "sleep disturbance," "sleep deprivation," "sleep quality," "insomnia," "obstructive sleep apnea," "circadian rhythm disorders," "obesity," "body mass index," "glycemic control," "HbA1c," "insulin resistance," "type 2 diabetes mellitus," "metabolic syndrome," and "primary care."

Studies published between January 2005 and June 2026 were considered eligible to ensure inclusion of both landmark investigations and contemporary evidence. Preference was given to studies published within the last ten years when multiple sources addressed similar research questions. Included publications comprised systematic reviews, meta-analyses, randomized controlled trials, prospective cohort studies, cross-sectional studies, case-control studies, clinical guidelines, and consensus statements. Reference lists of key articles were also manually reviewed to identify additional relevant publications.

Studies were included if they investigated relationships between sleep disturbances and obesity, sleep disturbances and glycemic outcomes, obesity and sleep disorders, or integrated interactions among all three variables. Research involving adult populations aged 18 years and older was prioritized due to the focus on primary care populations. Studies examining sleep interventions and their effects on metabolic outcomes were also

included. Exclusion criteria included non-English publications, conference abstracts lacking full-text availability, studies focused exclusively on pediatric populations, and investigations involving highly specialized populations not representative of primary care settings.

Data extraction focused on study design, sample characteristics, sleep assessment methods, obesity measures, glycemic outcomes, major findings, and clinical implications. Particular attention was given to evidence describing mechanistic pathways, longitudinal associations, and intervention outcomes. Findings were synthesized thematically to identify recurring patterns and emerging concepts relevant to primary care practice.

The review process emphasized evidence quality and clinical relevance. Meta-analyses, large prospective cohorts, and randomized trials were prioritized when evaluating causal relationships and intervention effectiveness. Narrative synthesis was employed to integrate findings across heterogeneous study designs and to provide a comprehensive overview of current knowledge regarding the interconnected relationships among sleep disturbance, obesity, and glycemic control.

3. EPIDEMIOLOGY OF SLEEP DISTURBANCE IN PRIMARY CARE POPULATIONS

Sleep disturbances represent one of the most prevalent yet underrecognized health concerns encountered in primary care practice. Over the past two decades, growing evidence has demonstrated a substantial increase in the prevalence of sleep-related disorders worldwide, coinciding with parallel increases in obesity and T2DM. Current estimates suggest that approximately 30–45% of adults experience at least one chronic sleep complaint, while nearly 10–20% meet diagnostic criteria for a clinically significant sleep disorder requiring medical intervention [18,19]. The burden of sleep disturbances is particularly high among patients attending primary healthcare facilities, where obesity, hypertension, diabetes, cardiovascular disease, depression, and anxiety frequently coexist.

Population-based studies have consistently demonstrated a progressive decline in average sleep duration over recent decades. Historically, adults in industrialized countries averaged approximately 8–9 hours of sleep per night. Contemporary surveys indicate that many adults now obtain less than 7 hours of sleep, falling below recommendations established by the American Academy of Sleep Medicine and the Sleep Research Society [20]. This reduction in sleep duration has been attributed to technological advances, increased screen exposure, occupational demands, social commitments, shift work, and lifestyle changes associated with urbanization [21].

Insomnia remains the most frequently reported sleep disorder in primary care settings. Epidemiological investigations estimate that approximately one-third of adult's experience symptoms of insomnia, while 10–15% fulfill diagnostic criteria for chronic insomnia disorder [22]. The prevalence is considerably higher among women, older adults, individuals with obesity, and patients with chronic medical conditions. Insomnia has been associated with increased risk of weight gain, metabolic syndrome, impaired glucose tolerance, and cardiovascular disease [23].

OSA has emerged as a particularly important contributor to metabolic dysfunction. The prevalence of OSA among adults is estimated to range between 9% and 38%, depending on population characteristics and diagnostic criteria [24]. Among patients with obesity, prevalence rates may exceed 60–70%, highlighting the strong association between excess adiposity and upper airway obstruction during sleep [25]. Notably, many individuals with OSA remain undiagnosed, particularly within primary care populations where routine sleep assessments are often lacking. This underdiagnosis is clinically significant because untreated OSA contributes to hypertension, insulin resistance, diabetes progression, cardiovascular disease, and reduced quality of life [26].

The epidemiological relationship between sleep duration and obesity has been extensively investigated. Meta-analyses involving hundreds of thousands of participants have consistently demonstrated that short sleep duration is associated with increased obesity risk [27]. Individuals sleeping fewer than six hours per night exhibit significantly higher odds of obesity compared with those obtaining seven to eight hours of sleep. Furthermore, longitudinal studies suggest that chronic sleep restriction predicts future weight gain independent of dietary intake and physical activity levels [28].

Similarly, sleep disturbances are highly prevalent among individuals with diabetes. Studies report that between 50% and 80% of patients with T2DM experience clinically significant sleep problems [29]. These include insomnia, OSA, excessive daytime sleepiness, restless legs syndrome, and poor sleep quality. Importantly, sleep disturbances among diabetic patients are associated with higher HbA1c levels, increased medication requirements, greater

risk of complications, and poorer health-related quality of life [30].

Within primary care populations, the coexistence of sleep disorders, obesity, and diabetes represents a substantial challenge. Data from large cohort studies indicate that patients with obesity are approximately twice as likely to report sleep disturbances compared with individuals of normal weight [31]. Similarly, patients with T2DM demonstrate significantly higher rates of sleep complaints than non-diabetic controls. These observations suggest that sleep assessment should be considered a routine component of chronic disease management in primary healthcare settings.

The economic implications of sleep disturbances are also considerable. Sleep disorders contribute to increased healthcare utilization, reduced workplace productivity, absenteeism, occupational injuries, and motor vehicle accidents [32]. Healthcare expenditures associated with obesity and diabetes are further amplified when sleep disorders remain untreated. Consequently, addressing sleep health within primary care may yield both clinical and economic benefits.

Recent studies conducted in Middle Eastern populations have demonstrated patterns similar to those observed globally. High rates of obesity, diabetes, and sleep disorders have been reported throughout Gulf Cooperation Council countries, including Saudi Arabia, where rapid socioeconomic transitions have influenced lifestyle behaviors and sleep patterns [33]. These findings underscore the importance of understanding sleep-related determinants of metabolic disease within regional healthcare systems

Table 1: Common Sleep Disturbances Encountered in Primary Care and Their Metabolic Consequences.

Sleep Disorder	Prevalence in Adults	Major Characteristics	Metabolic Consequences
Insomnia	10–15%	Difficulty initiating or maintaining sleep	Insulin resistance, weight gain
Short Sleep Duration	25–35%	<6–7 hours/night	Increased appetite, obesity
Obstructive Sleep Apnea	9–38%	Recurrent airway obstruction	Poor glycemic control
Circadian Rhythm Disorder	5–15%	Sleep-wake misalignment	Metabolic syndrome
Restless Legs Syndrome	5–10%	Unpleasant leg sensations	Sleep fragmentation
Excessive Daytime Sleepiness	Variable	Persistent daytime fatigue	Reduced physical activity

4. SLEEP PHYSIOLOGY AND METABOLIC REGULATION

Understanding the relationship between sleep and metabolic health requires an appreciation of normal sleep physiology. Sleep is regulated by two primary biological systems: the homeostatic sleep drive and the circadian timing system. Together, these systems coordinate sleep duration, timing, and quality while influencing numerous physiological processes involved in energy balance and glucose regulation [34].

Sleep consists of two major states: non-rapid eye movement (NREM) sleep and rapid eye movement (REM) sleep. NREM sleep is further divided into stages N1, N2, and N3, with N3 representing slow-wave sleep, the deepest and most restorative sleep stage. During slow-wave sleep, significant metabolic and hormonal processes occur, including growth hormone secretion, tissue repair, immune regulation, and glucose metabolism [35].

Sleep exerts profound effects on endocrine function. Several hormones critical for metabolic regulation follow circadian patterns closely linked to sleep-wake cycles. Growth hormone is predominantly secreted during slow-wave sleep and contributes to protein synthesis, lipolysis, and tissue regeneration [36]. Cortisol, a glucocorticoid hormone involved in glucose metabolism and stress responses, exhibits a circadian rhythm characterized by low nocturnal levels and a morning peak. Sleep disruption alters these hormonal patterns, potentially contributing to metabolic dysfunction [37].

Leptin and ghrelin represent two key hormones involved in appetite regulation. Leptin, produced primarily by adipose tissue, promotes satiety and suppresses food intake. Ghrelin, secreted by the stomach, stimulates appetite and food-seeking behavior. Sleep deprivation has been shown to decrease leptin concentrations while increasing ghrelin levels, creating a hormonal environment that favors increased caloric consumption and weight gain [38].

Insulin sensitivity is also influenced by sleep. During normal sleep, insulin responsiveness is maintained through coordinated hormonal and autonomic regulation. Experimental studies have demonstrated that even a few nights of restricted sleep can reduce insulin sensitivity by up to 25%, producing metabolic changes comparable to those observed during early diabetes development [39]. Sleep restriction increases hepatic glucose production, impairs peripheral glucose uptake, and alters pancreatic β-cell function, contributing to hyperglycemia and insulin resistance [40].

The autonomic nervous system plays an

additional role in mediating the effects of sleep on metabolism. Healthy sleep is associated with parasympathetic predominance, promoting cardiovascular recovery and metabolic stability. Sleep fragmentation and deprivation increase sympathetic nervous system activity, resulting in elevated catecholamine levels, increased blood pressure, enhanced lipolysis, and impaired insulin sensitivity [41].

Inflammation represents another important pathway linking sleep and metabolic health. Sleep loss is associated with increased circulating concentrations of inflammatory cytokines, including interleukin-6, tumor necrosis factor-alpha, and C-reactive protein [42]. Chronic low-grade inflammation contributes to obesity-related insulin resistance and has been implicated in the pathogenesis of T2DM and cardiovascular disease.

Emerging research also highlights the role of the gut microbiome in mediating interactions between sleep and metabolism. Sleep disturbances alter microbial diversity and composition, potentially influencing energy harvest, inflammatory pathways, and insulin sensitivity [43]. These findings suggest that sleep-related metabolic effects may involve interactions among neuroendocrine, immune, and gastrointestinal systems.

Collectively, these physiological observations support the concept that sleep serves as a critical regulator of metabolic homeostasis. Disruption of normal sleep architecture and duration may therefore have profound consequences for obesity development and glycemic regulation (Figure1).



5. BIOLOGICAL MECHANISMS LINKING SLEEP DISTURBANCE AND OBESITY

The relationship between sleep disturbance and obesity is multifactorial, involving complex interactions among neuroendocrine regulation, appetite control, energy expenditure, circadian biology, inflammatory signaling, and behavioral factors. Contemporary evidence suggests that inadequate sleep not only accompanies obesity but may actively contribute to its development through several interconnected pathways.

One of the most extensively studied mechanisms involves hormonal regulation of appetite. Experimental sleep restriction studies have demonstrated consistent reductions in circulating leptin levels accompanied by elevations in ghrelin concentrations [44]. These hormonal changes increase hunger, reduce satiety, and enhance cravings for calorie-dense foods rich in carbohydrates and fats. Consequently, sleep-deprived individuals often consume significantly more calories than well-rested individuals.

Beyond hormonal influences, sleep deprivation affects central nervous system pathways involved in

food reward. Functional magnetic resonance imaging studies have revealed enhanced activation of reward-related brain regions, including the nucleus accumbens and orbitofrontal cortex, following sleep restriction [45]. These neural alterations increase the motivational value of highly palatable foods and reduce inhibitory control over eating behaviors.

Another important mechanism involves reduced energy expenditure. Individuals experiencing inadequate sleep frequently report daytime fatigue, reduced motivation, and lower levels of physical activity. This decrease in energy expenditure may contribute to positive energy balance and gradual weight gain over time [46].

Sleep disturbances also influence adipose tissue biology. Chronic sleep deprivation promotes adipocyte dysfunction, increases visceral fat accumulation, and enhances secretion of pro-inflammatory adipokines [47]. Visceral adiposity is particularly important because it is strongly associated with insulin resistance, metabolic syndrome, and cardiovascular disease.

Inflammatory pathways represent another major contributor. Chronic sleep loss increases production of inflammatory mediators that interfere with insulin signaling and promote adipose tissue expansion [48]. These inflammatory responses may further exacerbate obesity-related metabolic dysfunction.

Circadian disruption additionally contributes to obesity risk. Modern lifestyles characterized by irregular sleep schedules, shift work, and nighttime light exposure can disrupt circadian regulation of metabolism. Circadian misalignment alters nutrient processing, glucose tolerance, and energy expenditure, promoting weight gain even in the absence of increased caloric intake [49].

The interaction between sleep disturbance and obesity is therefore not merely associative but appears to involve multiple causal pathways. These mechanisms collectively support the growing recognition of sleep health as a fundamental component of obesity prevention and management

6. BIOLOGICAL MECHANISMS LINKING SLEEP DISTURBANCE AND OBESITY

The biological pathways linking sleep disturbance and obesity are complex and involve interactions among neuroendocrine regulation, appetite control, energy metabolism, inflammatory responses, circadian rhythms, and central nervous system reward pathways. Understanding these mechanisms is essential for appreciating how sleep influences body weight and metabolic health.

One of the most extensively studied pathways involves hormonal regulation of appetite. Leptin and ghrelin are key hormones responsible for regulating hunger and satiety. Leptin is produced by adipose tissue and acts within the hypothalamus to suppress appetite and increase energy expenditure. Ghrelin is secreted primarily by the stomach and stimulates hunger and food-seeking behaviors [1]. Experimental sleep restriction studies have consistently demonstrated decreased leptin concentrations and increased ghrelin levels following inadequate sleep [2]. These hormonal changes result in increased hunger, reduced satiety, and greater caloric consumption.

Sleep deprivation additionally influences central nervous system pathways involved in food reward. Functional neuroimaging studies reveal increased activation of reward-related brain regions, including the nucleus accumbens, amygdala, and orbitofrontal cortex, following sleep restriction [3]. These alterations increase the motivational value of highly palatable foods rich in sugar and fat while reducing inhibitory control mechanisms that normally regulate food intake. Consequently, sleep-deprived individuals frequently consume greater quantities of calorie-dense foods.

Cortisol represents another important mediator of sleep-related weight gain. Sleep loss activates the HPA axis, resulting in elevated cortisol secretion [4]. Chronically elevated cortisol promotes visceral adiposity, increases appetite, and contributes to insulin resistance. Central obesity associated with cortisol excess is particularly concerning because of its strong relationship with cardiometabolic disease.

Inflammatory pathways also contribute substantially to obesity development. Chronic sleep deprivation increases circulating levels of pro-inflammatory cytokines such as TNF-α, IL-6, and CRP [5]. These inflammatory mediators influence appetite regulation, insulin signaling, adipocyte function, and energy metabolism. Chronic low-grade inflammation is now recognized as a key feature of obesity and may represent a major mechanism linking sleep disturbance and metabolic dysfunction.

Circadian biology provides another important framework for understanding sleep-related obesity. Circadian clocks regulate numerous physiological processes involved in metabolism, including glucose regulation, lipid metabolism, hormone secretion, and feeding behavior [6]. Circadian disruption resulting from shift work, irregular sleep schedules, or nighttime light exposure may impair metabolic efficiency and promote weight gain even in the absence of increased caloric intake.

Energy expenditure is also influenced by sleep. Sleep-deprived individuals frequently report fatigue, reduced physical activity, and lower exercise participation [7]. This reduction in energy expenditure may contribute to positive energy balance and gradual weight gain. Furthermore, inadequate sleep may impair recovery following physical activity, reducing adherence to exercise programs.

Emerging evidence suggests that alterations in the gut microbiome may mediate some of the effects of sleep deprivation on obesity. Sleep disturbances have been associated with changes in microbial diversity and composition that may influence energy harvest, inflammatory signaling, and metabolic regulation [8]. Although research in this area remains relatively new, these findings highlight the complex interactions between sleep and metabolic health.

Overall, the biological relationship between sleep disturbance and obesity involves multiple interconnected pathways that collectively favor weight gain, adiposity, and metabolic dysfunction. These mechanisms support the concept that sleep health should be considered an essential component of obesity prevention and treatment.

Table 2: Biological Mechanisms Linking Sleep Disturbance to Obesity.

Mechanism	Physiological Change	Consequence
Leptin Reduction	Reduced satiety signaling	Increased food intake
Ghrelin Elevation	Enhanced hunger stimulation	Increased appetite
Cortisol Elevation	Increased visceral fat deposition	Central obesity
Sympathetic Activation	Metabolic stress response	Weight gain
Inflammation	Elevated TNF-α and IL-6	Insulin resistance
Circadian Disruption	Altered metabolic timing	Obesity risk
Reward System Activation	Increased food reward sensitivity	Excess caloric intake
Reduced Physical Activity	Lower energy expenditure	Positive energy balance

7. SLEEP DISTURBANCE AND INSULIN RESISTANCE

Insulin resistance represents a central mechanism connecting sleep disturbances, obesity, and diabetes. Defined as a diminished biological response to insulin within target tissues such as skeletal muscle, adipose tissue, and the liver, insulin resistance contributes to hyperglycemia, metabolic syndrome, and T2DM development [9].

Experimental evidence demonstrates that even short periods of sleep restriction can significantly impair insulin sensitivity. Healthy adults subjected to restricted sleep schedules exhibit reductions in glucose tolerance and insulin responsiveness comparable to those observed during early diabetes development [10]. These findings suggest that sleep deprivation may function as an independent metabolic stressor capable of initiating pathological changes before overt diabetes becomes apparent.

Several physiological pathways explain this relationship. Elevated cortisol levels resulting from HPA-axis activation impair insulin signaling and increase hepatic glucose production [11]. Simultaneously, increased sympathetic nervous system activity elevates circulating catecholamines, further reducing insulin sensitivity and promoting hyperglycemia.

Sleep fragmentation appears particularly detrimental to insulin regulation. Frequent nocturnal awakenings reduce slow-wave sleep duration, a sleep stage strongly associated with glucose homeostasis and insulin sensitivity [12]. Studies utilizing polysomnography have demonstrated that reductions in slow-wave sleep correlate with impaired glucose tolerance and elevated fasting glucose levels.

Inflammation also plays a crucial role. Increased concentrations of IL-6, TNF-α, and CRP interfere with insulin receptor signaling and reduce glucose uptake within peripheral tissues [13]. Chronic inflammation associated with sleep deprivation therefore contributes directly to insulin resistance and diabetes risk.

Importantly, sleep-related insulin resistance is not limited to individuals with obesity. Several investigations have demonstrated impaired insulin sensitivity among normal-weight individuals experiencing chronic sleep deprivation [14]. These observations indicate that sleep disturbances may independently contribute to metabolic disease, regardless of body weight.

Prospective studies further support these findings. Individuals reporting chronic insomnia, poor sleep quality, or short sleep duration exhibit significantly greater risks of developing insulin resistance and T2DM over time [15]. These relationships remain significant after adjustment for age, sex, BMI, physical activity, and dietary factors.

Recognition of sleep disturbances as contributors to insulin resistance has important implications for primary care practice. Early identification and

treatment of sleep problems may represent an effective strategy for preventing progression from insulin resistance to overt diabetes.

8. SLEEP DISTURBANCE AND GLYCEMIC CONTROL

Glycemic control is a cornerstone of diabetes management and is strongly associated with the risk of microvascular and macrovascular complications. Glycemic status is commonly assessed using fasting plasma glucose, postprandial glucose levels, continuous glucose monitoring metrics, and glycated hemoglobin (HbA1c). Emerging evidence indicates that sleep duration, sleep quality, sleep architecture, and circadian alignment significantly influence glycemic regulation and diabetes outcomes [16].

Over the past decade, numerous observational studies have demonstrated a consistent association between poor sleep and impaired glycemic control. Individuals experiencing chronic sleep deprivation often exhibit elevated fasting glucose levels, increased insulin resistance, and higher HbA1c values compared with individuals obtaining adequate sleep [17]. These relationships have been observed among healthy adults, patients with prediabetes, and individuals with established T2DM.

Sleep duration appears to have a nonlinear relationship with glycemic outcomes. Several large cohort studies have reported a U-shaped association, whereby both short sleep duration (<6 hours per night) and excessively long sleep duration (>9 hours per night) are associated with increased diabetes risk [18]. Short sleep duration is thought to exert direct physiological effects on glucose metabolism, whereas prolonged sleep may reflect underlying illness, depression, sedentary behavior, or other factors contributing to metabolic dysfunction.

The effects of sleep quality are equally important. Individuals reporting fragmented sleep, frequent nocturnal awakenings, difficulty maintaining sleep, or poor subjective sleep quality often demonstrate poorer glycemic control regardless of total sleep duration [19]. Sleep fragmentation reduces slow-wave sleep, a stage closely linked to glucose homeostasis and insulin sensitivity. Consequently, repeated disruptions of sleep continuity may contribute significantly to metabolic dysregulation.

Experimental sleep restriction studies provide strong evidence supporting causality. Controlled laboratory investigations have demonstrated that restricting sleep to four to five hours per night for several consecutive nights results in significant reductions in insulin sensitivity, impaired glucose tolerance, and increased fasting glucose concentrations [20]. These metabolic alterations resemble those observed during early stages of T2DM and suggest that chronic sleep deprivation may accelerate disease progression.

Behavioral mechanisms further contribute to poor glycemic outcomes. Sleep-deprived individuals frequently consume greater quantities of calorie-dense foods, engage in less physical activity, and demonstrate poorer adherence to healthy lifestyle recommendations [21]. These behaviors may worsen obesity and contribute indirectly to deteriorating glycemic control.

Among patients with established diabetes, sleep disturbances often arise as a consequence of disease-related complications. Hyperglycemia may cause nocturia, thirst, dehydration, and discomfort, resulting in frequent nighttime awakenings. Similarly, diabetic peripheral neuropathy may produce pain and paresthesia that interfere with sleep continuity [22]. Hypoglycemic episodes occurring during sleep can also provoke autonomic activation characterized by sweating, palpitations, tremors, and awakening. These symptoms disrupt sleep and may contribute to fear of nocturnal hypoglycemia among insulin-treated patients.

Recent studies utilizing continuous glucose monitoring systems have provided further insights into the relationship between sleep and glycemic variability. Patients with fragmented sleep frequently exhibit greater overnight glucose fluctuations and elevated morning glucose levels compared with individuals achieving consolidated sleep [23]. Glycemic variability has emerged as an important predictor of oxidative stress, endothelial dysfunction, and diabetes complications.

Psychological factors also play a significant role. Depression, anxiety, diabetes-related distress, and chronic stress commonly coexist with sleep disturbances and poor glycemic control [24]. Psychological distress may impair adherence to treatment plans, promote unhealthy eating behaviors, and contribute to both sleep problems and hyperglycemia.Clinical intervention studies provide encouraging evidence that improving sleep may positively affect glycemic outcomes. Sleep extension interventions, cognitive behavioral therapy for insomnia (CBT-I), treatment of OSA, and circadian rhythm interventions have demonstrated modest improvements in HbA1c levels and insulin sensitivity in selected populations [25]. Although further research is required, these findings support incorporation of sleep assessment and management into comprehensive diabetes care.

Overall, available evidence strongly suggests that

sleep health represents a significant determinant of glycemic control. Addressing sleep disturbances may therefore enhance conventional diabetes management strategies and improve long-term outcomes among patients with metabolic disease.

Table 3: Effects Of Sleep Disturbances on Glycemic Outcomes.

Sleep Disturbance	Physiological Effect	Glycemic Consequence
Short Sleep Duration	Reduced insulin sensitivity	Elevated fasting glucose
Poor Sleep Quality	Sleep fragmentation	Increased HbA1c
Insomnia	HPA-axis activation	Hyperglycemia
OSA	Intermittent hypoxia	Insulin resistance
Circadian Misalignment	Hormonal disruption	Impaired glucose tolerance
Excessive Daytime Sleepiness	Reduced physical activity	Poor diabetes control

9. OBSTRUCTIVE SLEEP APNEA, OBESITY, AND DIABETES

OSA represents one of the most important clinical intersections between sleep disturbance, obesity, and metabolic disease. Characterized by recurrent episodes of partial or complete upper airway obstruction during sleep, OSA results in intermittent hypoxia, sleep fragmentation, excessive daytime sleepiness, and activation of multiple pathophysiological pathways implicated in cardiometabolic disease [26].

OSA affects millions of adults worldwide and is strongly associated with obesity. Excess adipose tissue surrounding the upper airway contributes to airway narrowing and increased collapsibility during sleep. Central obesity, increased neck circumference, and visceral adiposity are particularly important risk factors [27]. Epidemiological studies indicate that approximately 60–70% of patients with moderate-to-severe OSA are overweight or obese.

The metabolic consequences of OSA extend beyond sleep disruption. Recurrent episodes of intermittent hypoxia trigger oxidative stress, systemic inflammation, endothelial dysfunction, and sympathetic nervous system activation [28]. These physiological responses impair insulin signaling, reduce glucose utilization, and contribute to insulin resistance.

Several large cohort studies have demonstrated independent associations between OSA severity and T2DM prevalence. Importantly, these associations frequently persist after adjustment for BMI, suggesting that OSA contributes to metabolic dysfunction independently of obesity [29]. Patients with moderate-to-severe OSA often exhibit higher fasting glucose concentrations, elevated HbA1c levels, and greater insulin resistance than individuals without sleep-disordered breathing.

Intermittent hypoxia appears to play a central role in mediating these effects. Animal and human studies have shown that repeated hypoxic episodes impair pancreatic β-cell function, increase oxidative stress, and promote inflammatory responses that interfere with glucose metabolism [30]. Furthermore, sympathetic activation increases hepatic glucose production and exacerbates hyperglycemia.

OSA also contributes significantly to cardiovascular risk. Hypertension, dyslipidemia, endothelial dysfunction, coronary artery disease, and stroke occur more frequently among patients with untreated OSA [31]. Given the already elevated cardiovascular risk associated with obesity and diabetes, the coexistence of OSA may substantially worsen long-term outcomes.

Continuous Positive Airway Pressure (CPAP) remains the gold-standard treatment for moderate-to-severe OSA. CPAP prevents airway collapse during sleep, improves oxygenation, reduces sleep fragmentation, and alleviates daytime symptoms [32]. Numerous studies have demonstrated improvements in quality of life, daytime functioning, and blood pressure control following CPAP initiation.

The effects of CPAP on glycemic control have been investigated extensively. Although results vary, several studies have reported improvements in insulin sensitivity and modest reductions in HbA1c among patients demonstrating good treatment adherence [33]. Weight reduction, when combined with CPAP therapy, may produce even greater metabolic benefits.

Given the high prevalence of undiagnosed OSA among patients with obesity and diabetes, routine screening in primary care settings is strongly recommended. Screening instruments such as the STOP-BANG questionnaire offer practical methods for identifying high-risk individuals who may benefit from diagnostic sleep testing [34].

10. CIRCADIAN RHYTHM DISORDERS AND METABOLIC DYSFUNCTION

Circadian rhythms are endogenous biological cycles that regulate physiological functions over a 24-hour period. These rhythms are coordinated by the

suprachiasmatic nucleus located within the hypothalamus and are synchronized primarily through environmental light exposure [35]. Circadian regulation influences sleep-wake patterns, hormone secretion, appetite, glucose metabolism, cardiovascular function, and immune activity.

Modern lifestyles increasingly disrupt circadian alignment. Shift work, irregular sleep schedules, transmeridian travel, nighttime light exposure, and social jet lag may cause circadian misalignment, a condition in which behavioral schedules become desynchronized from internal biological rhythms [36]. Growing evidence suggests that circadian disruption contributes significantly to obesity, insulin resistance, and diabetes risk.

One mechanism involves altered timing of hormone secretion. Circadian misalignment disrupts normal patterns of cortisol, melatonin, insulin, and growth hormone release [37]. These hormonal disturbances impair glucose regulation and may promote weight gain. Experimental studies have demonstrated that even short periods of circadian disruption reduce insulin sensitivity and impair glucose tolerance.

Shift workers represent an important population for studying these effects. Numerous epidemiological investigations have reported increased prevalence of obesity, metabolic syndrome, and T2DM among shift workers compared with daytime workers [38]. The combination of circadian disruption and sleep deprivation may amplify metabolic risk substantially.

Meal timing represents another important factor. Consuming food during biological nighttime has been associated with impaired glucose tolerance, higher postprandial glucose excursions, and greater obesity risk [39]. These findings suggest that metabolic responses vary according to circadian phase and highlight the importance of synchronizing eating patterns with biological rhythms.

Recent advances in chronobiology have led to growing interest in chrononutrition and circadian-based interventions. Strategies aimed at improving circadian alignment, such as maintaining regular sleep schedules, optimizing light exposure, and restricting food intake to daytime hours, may offer additional benefits for metabolic health [40].

The recognition of circadian rhythms as major regulators of metabolism has important implications for primary care. Incorporating assessment of sleep timing and work schedules into routine metabolic evaluations may improve identification of high-risk individuals and support development of more personalized treatment approaches.

11. CONCLUSION

Sleep disturbance, obesity, and impaired glycemic control represent three highly prevalent and interrelated health concerns that increasingly challenge primary healthcare systems worldwide. The evidence reviewed in this manuscript demonstrates that sleep is not merely a restorative physiological process but rather a critical regulator of metabolic homeostasis, energy balance, hormonal function, inflammatory pathways, and glucose metabolism. Consequently, disturbances in sleep duration, quality, architecture, and circadian timing can substantially influence the development and progression of obesity, insulin resistance, metabolic syndrome, and T2DM.

Current epidemiological evidence consistently demonstrates strong associations between inadequate sleep and adverse metabolic outcomes. Individuals experiencing chronic sleep deprivation, insomnia, poor sleep quality, OSA, or circadian misalignment exhibit higher risks of obesity, impaired glucose tolerance, insulin resistance, and diabetes. Importantly, these associations persist after adjustment for traditional risk factors, suggesting that sleep disturbances may function as independent contributors to metabolic dysfunction. Furthermore, obesity itself contributes to sleep abnormalities through mechanical airway obstruction, systemic inflammation, hormonal dysregulation, and altered respiratory physiology, creating a bidirectional relationship that perpetuates disease progression.

The mechanisms underlying these associations are multifactorial and involve complex interactions among neuroendocrine, inflammatory, autonomic, behavioral, and circadian pathways. Sleep deprivation alters appetite regulation through reductions in leptin and elevations in ghrelin, promoting increased food intake and weight gain. Simultaneously, activation of the hypothalamic-pituitary-adrenal axis, sympathetic nervous system stimulation, chronic low-grade inflammation, and oxidative stress impair insulin sensitivity and glucose regulation. Emerging evidence further suggests important roles for circadian biology and the gut microbiome in mediating sleep-related metabolic effects.

Among the various sleep disorders, OSA appears particularly important because of its high prevalence among individuals with obesity and diabetes. Intermittent hypoxia, sleep fragmentation, and sympathetic activation associated with OSA contribute directly to insulin resistance and poor

glycemic control. Early recognition and treatment of OSA may therefore represent a valuable strategy for improving metabolic outcomes and reducing cardiovascular risk.

The findings of this review have important implications for primary care practice. Given the high prevalence of sleep disturbances among patients with obesity and diabetes, routine sleep assessment should be incorporated into comprehensive metabolic evaluations. Validated screening tools such as the Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, Insomnia Severity Index, and STOP-BANG questionnaire provide practical methods for identifying patients who may benefit from further assessment and intervention. Integrating sleep health into chronic disease management may improve patient outcomes beyond those achievable through conventional dietary and physical activity interventions alone.

Management strategies should adopt a multidisciplinary and patient-centered approach. Sleep hygiene education, weight reduction programs, CBT-I, treatment of OSA, circadian rhythm optimization, and lifestyle modification should be considered complementary components of metabolic disease management. Such interventions may improve sleep quality, enhance insulin sensitivity, facilitate weight loss, and contribute to better glycemic control.

Future research should focus on large prospective studies capable of clarifying causal relationships and identifying optimal intervention strategies. Additional randomized controlled trials are needed to determine the long-term effects of sleep-targeted interventions on obesity prevention, diabetes management, and cardiovascular outcomes. Emerging technologies, including wearable sleep monitoring devices, continuous glucose monitoring systems, and precision medicine approaches, may further improve understanding and management of sleep-related metabolic dysfunction.

In conclusion, sleep health should be recognized as a fundamental pillar of metabolic health alongside nutrition and physical activity. Addressing sleep disturbances within primary care settings offers a promising opportunity to improve obesity management, enhance glycemic control, reduce diabetes-related complications, and ultimately improve population health outcomes.

REFERENCES

Ahmed AE, Al-Jahdali F, AlALwan A, et al. sleep disorders in Saudi Arabia. Ann Thorac Med. 2017;12(2):98–103.

Baron KG, Reid KJ. Circadian disruption and obesity. Sleep Med Clin. 2014;9(3):297–303.

Benedict C, Vogel H, Jonas W, et al. Gut microbiota and sleep interactions. Int J Obes. 2016;40(3):397–400.

Borzouei S, et al. Sleep quality and glycemic control in adults with T2DM. BMC Endocr Disord. 2024.

Buxton OM, Cain SW, O'Connor SP, et al. Adverse metabolic consequences of insufficient sleep. Sci Transl Med. 2012;4(129):129ra43.

Buysse DJ. Sleep health: can we define it? Does it matter? Sleep. 2014;37(1):9–17.

Cappuccio FP, D'Elia L, Strazzullo P, Miller MA. Quantity and quality of sleep and incidence of T2DM. Diabetes Care. 2010;33(2):414–20.

Cappuccio FP, Taggart FM, Kandala NB, et al. Meta-analysis of sleep duration and obesity. Sleep. 2008;31(5):619–26.

Chaput JP, Dutil C. Lack of sleep as a contributor to obesity in adolescents and adults. Curr Obes Rep. 2016;5(4):500–7.

Chasens ER, Korytkowski M, Sereika SM, Burke LE. Sleep quality and diabetes self-management. Diabetes Educ. 2013;39(1):74–82.

Chen Y, et al. Insomnia and glycemic control: systematic review and meta-analysis. J Glob Health. 2025; 15:04016.

Cizza G, Requena M, Galli G, de Jonge L. Sleep deprivation and obesity. Trends Endocrinol Metab. 2011;22(7):273–81.

Foster GD, Borradaile KE, Sanders MH, et al. Weight loss and sleep apnea. Arch Intern Med. 2009;169(17):1619–26.

Gangwisch JE, Malaspina D, Boden-Albala B, Heymsfield SB. Sleep duration and obesity risk. Sleep. 2005;28(10):1289–96.

Grandner MA. Sleep, health, and society. Sleep Med Clin. 2017;12(1):1–22.

Greer SM, Goldstein AN, Walker MP. Sleep deprivation and food desire. Nat Commun. 2013; 4:2259.

Henson J, et al. Importance of sleep in T2DM management. Diabetes Care. 2024;47(3):331–339.

Hillman DR, Murphy AS, Antic R. Economic consequences of sleep disorders. Sleep Med Rev. 2006;10(3):167–78.
Irwin MR, Opp MR. Sleep health and inflammation. Nat Rev Immunol. 2017;17(11):701–12.
Irwin MR. Why sleep is important for health. Annu Rev Psychol. 2015; 66:143–72.
Javaheri S, Redline S. Sleep disorders and cardiometabolic risk. Circulation. 2017;136(9)–e17.
Knutson KL, Ryden AM, Mander BA, Van Cauter E. Sleep and diabetes severity. Arch Intern Med. 2006;166(16):1768–74.
Leproult R, Van Cauter E. Growth hormone and sleep. Lancet. 2010;375(9718):987–99.
Leproult R, Van Cauter E. Role of sleep in metabolic regulation. Lancet. 2010;375(9718):987–99.
Liu Y, Wheaton AG, Chapman DP, et al. Trends in sleep duration. Sleep. 2016;39(5):1155–62.
Medic G, Wille M, Hemels MEH. Health consequences of sleep disruption. Sleep Med Rev. 2017; 32:91–101.
Mostafa A, et al. Sleep interventions and HbA1c reduction. J Int Med Res. 2025.
Nedeltcheva AV, Kilkus JM, Imperial J, et al. Sleep restriction and energy expenditure. Am J Clin Nutr. 2009;89(1):126–33.
Ohayon MM. Epidemiology of insomnia. Sleep Med Rev. 2002;6(2):97–111.
Pamidi S, Tasali E. OSA and diabetes. Chest. 2012;141(3):674–84.
Patel SR, Hu FB. Short sleep duration and weight gain. Obesity. 2008;16(3):643–53.
Peppard PE, Young T, Barnet JH, et al. Increased prevalence of sleep-disordered breathing. Am J Epidemiol. 2013;177(9):1006–14.
Punjabi NM. Epidemiology of OSA. Proc Am Thorac Soc. 2008;5(2):136–43.
Reaven GM. Insulin resistance syndrome. Diabetes. 1988;37(12):1595–607.
Reutrakul S, Van Cauter E. Sleep influences on obesity and diabetes. Lancet Diabetes Endocrinol. 2014;2(10):819–28.
Scheer FAJL, Hilton MF, Mantzoros CS, Shea SA. Circadian misalignment and metabolic risk. Proc Natl Acad Sci USA. 2009;106(11):4453–8.
Shan Z, Ma H, Xie M, et al. Sleep duration and risk of T2DM. Diabetes Care. 2015;38(3):529–37.
Spiegel K, Leproult R, L'Hermite-Baleriaux M, et al. Ghrelin and leptin responses to sleep loss. J Clin Endocrinol Metab. 2004;89(11):5762–71.
Spiegel K, Tasali E, Penev P, Van Cauter E. Sleep curtailment and leptin levels. Ann Intern Med. 2004;141(11):846–50.
St-Onge MP. Sleep and obesity pathways. Sleep Health. 2017;3(5):347–52.
Tasali E, Leproult R, Ehrmann DA, Van Cauter E. Slow-wave sleep and glucose regulation. Proc Natl Acad Sci USA. 2008;105(3):1044–9.
Tasali E, Mokhlesi B, Van Cauter E. Sleep architecture and metabolism. J Clin Invest. 2008;118(3):881–8.
Van Cauter E, Knutson KL. Sleep and endocrine regulation. Sleep Med. 2008;9(Suppl 1)–55.
Van Cauter E, Knutson KL. Sleep and the epidemic of obesity in children and adults. Eur J Endocrinol. 2008;159(Suppl 1)–66.
Vgontzas AN, Liao D, Bixler EO, et al. Insomnia and metabolic disorders. Sleep. 2009;32(4):491–7.
Watson NF, Badr MS, Belenky G, et al. Recommended amount of sleep. Sleep. 2015;38(6):843–4.
World Health Organization. Diabetes Fact Sheet. Geneva: WHO; 2024.
World Health Organization. Obesity and overweight. Geneva: WHO; 2024.
Young T, Peppard PE, Gottlieb DJ. Epidemiology of OSA. Am J Respir Crit Care Med. 2002;165(9):1217–39.